Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDR Brachytherapy + Immunotherapy in Advanced Cancers
NCT04620603Phase 1Active, not recruiting
- Sponsor
- Case Comprehensive Cancer Center
- Start
- May 2021
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in melanoma, renal cell carcinoma (RCC) and urothelial carcinoma (UC), sponsored by Case Comprehensive Cancer Center. Primary endpoints: Tumor Response Assessed by iRECIST at 12 months and Tumor Response Assessed by RECIST v1.1 at 12 months. Started May 2021; status: active, not recruiting.
02
Conditions
melanomarenal cell carcinoma (RCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04620603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04620603.